

Quarterly Industry Update

As of December 31, 2016

Industry: Neurological Equipment



Industry Summary

Cogent Valuation identified Neurological Equipment publicly traded companies, IPOs, and recent M&A transactions within the Neurological Equipment industry, which provides a basis for market and transaction pricing that can be used by your firm in estimating market sentiment and its impact on your firm's value. Over the last year since December 31, 2015, the median 52-week share price return of the Neurological Equipment industry was -19.2%. Between December 31, 2014 and December 31, 2016, the median EV/EBITDA multiple increased from 14.6 to 15.9. Furthermore, the median price-to-earnings multiple increased from 36.8 to 39.9 over the same period.

Comparable Public Company Key Statistics


Median 52-Week Return	-19.2%	Median EV/Revenue Multiple	3.8x	Median Price/Earnings Multiple	39.9x
Median 3-Year CAGR Return	11.4%	Median EV/EBITDA Multiple	15.9x	Median EV/Gross CF Multiple	30.7x

Comparable Public Company Market Price Returns (As of December 31, 2016)


	YTD	3 Month	1 Year	2 Year	3 Year	5 Year	2015	2014	2013	2012	2011
EnteroMedics Inc.	-98.5%	-78.8%	-98.5%	-96.3%	-90.2%	-74.3%	-90.8%	-30.4%	-27.1%	64.7%	-44.8%
Globus Medical, Inc.	-10.8%	9.9%	-10.8%	2.2%	7.1%	N/A	17.0%	17.8%	92.4%	N/A	N/A
Integra LifeSciences Holdings Corporation	26.6%	3.9%	26.6%	25.8%	21.6%	22.7%	25.0%	13.7%	22.4%	26.4%	-34.8%
Natus Medical Incorporated	-27.6%	-11.4%	-27.6%	-1.7%	15.6%	29.8%	33.3%	60.2%	101.5%	18.4%	-33.5%
NeuroMetrix, Inc.	-62.7%	-52.7%	-62.7%	-69.2%	-60.2%	-52.3%	-74.6%	-33.2%	12.5%	-65.4%	-69.4%
NuVasive, Inc.	24.5%	1.1%	24.5%	19.5%	27.7%	39.9%	14.7%	45.9%	109.1%	22.8%	-50.9%
Median of Industry Public Companies	-19.2%	-5.2%	-19.2%	0.2%	11.4%	22.7%	15.9%	15.7%	57.4%	22.8%	-44.8%

(Multiple year periods are calculated as the average annual return.)

Median Quarterly Revenue Growth of All Neurological Equipment Companies



Median Gross Profit, EBITDA, Net Income and Gross Cash Flow Margins



Median Public Company Multiples of the Neurological Equipment Industry

Date:	12/31/2014	3/31/2015	6/30/2015	9/30/2015	12/31/2015	3/31/2016	6/30/2016	9/30/2016	12/31/2016
EV/Revenues Multiple	3.0x	2.9x	3.0x	3.2x	4.0x	3.1x	3.9x	3.9x	3.8x
EV/EBITDA Multiple	14.6x	15.6x	15.6x	14.2x	15.8x	15.4x	17.2x	17.3x	15.9x
Price/Earnings Multiple	36.8x	39.0x	47.5x	41.8x	39.1x	33.1x	26.1x	33.1x	39.9x
EV/Gross Cash Flows Multiple	30.8x	36.6x	32.8x	28.5x	29.7x	22.2x	27.3x	33.4x	30.7x

This industry research is provided at no charge to Cogent Valuation's clients. Research or detailed information not covered in this report can be obtained for a fee. Contact [Steven Kam](mailto:Steven.Kam@CogentValuation.com) at 415-392-0888 for additional information or questions in connection with this research report. Copyright © 2017 Cogent Valuation. All Rights Reserved.

Quarterly Industry Update

As of December 31, 2016

Industry: Neurological Equipment

Industry Initial Public Offerings (dollars in millions, except share prices)


Offer Date	Company Name	Offer Price	Shares Offered	Amount Raised	Total Assets	Debt	LTM Revenues	LTM EBITDA	LTM Net Income	LTM Cash Flows
11/3/2016	Neurotech International Limited	\$0.15	35.0	\$5.4	\$2.2	\$0.7	\$0.2	(\$2.7)	(\$3.3)	(\$2.6)
8/2/2012	Globus Medical, Inc.	\$12.00	8.3	\$100.0	\$354.8	\$0.0	\$347.9	\$121.4	\$63.9	\$138.8
6/27/2012	Tesaro, Inc.	\$13.50	6.0	\$81.0	\$93.0	\$0.0	\$0.0	(\$23.2)	(\$23.2)	(\$23.2)
4/30/2012	Supernus Pharmaceuticals, Inc.	\$5.00	3.4	\$50.0	\$53.7	\$29.5	\$0.8	(\$36.9)	\$53.8	(\$36.2)
2/10/2011	Kips Bay Medical, Inc.	\$8.00	2.1	\$16.5	\$7.2	\$0.0	\$0.1	(\$8.7)	(\$10.2)	(\$8.6)
2/2/2011	Tornier N.V.	\$19.00	8.8	\$166.3	\$499.2	\$133.8	\$223.4	\$13.2	(\$62.1)	\$28.6
11/23/2010	Anacor Pharmaceuticals, Inc.	\$5.00	12.0	\$60.0	\$20.4	\$9.1	\$31.1	(\$4.3)	(\$6.5)	(\$3.6)
11/22/2010	Zogenix, Inc.	\$4.00	7.1	\$56.0	\$55.0	\$35.9	\$14.6	(\$55.4)	(\$77.6)	(\$54.1)
8/13/2010	Electromed, Inc.	\$4.00	1.7	\$6.8	\$13.4	\$3.8	\$14.2	\$2.3	\$1.0	\$2.6
8/2/2010	Trius Therapeutics LLC	\$5.00	4.7	\$50.0	\$18.7	\$19.8	\$5.4	(\$18.8)	(\$20.4)	(\$18.1)
Median of All IPOs		nm	nm	\$53.0	\$37.0	\$6.4	\$9.8	(\$6.5)	(\$8.3)	(\$6.1)

nm: not meaningful, N/A: not applicable

Recent Merger and Acquisition Transactions for a Majority Stake (dollars in millions)

Transaction Date	Target	Acquirer	Transaction Size	% Bought
12/22/2014	Topera, Inc.	Abbott Laboratories	\$550.0	100%
10/1/2014	Triangle BioSystems, Inc.	Harvard Bioscience Inc.	\$2.1	100%
2/20/2014	NuPathe, Inc.	Teva Pharmaceutical Industries	\$280.6	100%
4/26/2013	Vichrom Human Bionics	Ergoresearch Ltd.	\$3.0	100%
1/28/2013	NeuroLogica Corp.	Samsung Electronics	\$153.7	100%
11/1/2012	Surpass Medical Ltd.	Stryker Corporation	\$135.0	100%
3/9/2012	NeuroDyne Medical, Corp.	Zynex NeuroDiagnostic	\$0.8	100%
2/16/2012	NeuroNexus Technologies	QiG Group, LLC	\$13.5	100%
2/14/2012	Synovis Life Technologies Inc.	Baxter International Inc.	\$312.7	100%
8/31/2011	PEAK Surgical, Inc.	Medtronic, Inc.	\$96.0	81%
8/31/2011	Salient Surgical Technologies	Medtronic, Inc.	\$452.0	91%
6/30/2011	ArthroCare, Parallax	NeuroTherm, Inc.	\$5.5	100%
5/23/2011	SeaSpine, Inc.	Integra LifeSciences	\$88.7	100%
5/20/2011	IS Pharma plc	Sinclair Pharma	\$79.1	100%
11/17/2010	AGA Medical Holdings, Inc.	St. Jude Medical Inc.	\$1,310.9	100%
9/27/2010	Micrus Endovascular Corp.	Codman & Shurtleff, Inc.	\$432.5	100%
8/12/2010	ATS Medical, Inc.	Medtronic, Inc.	\$358.8	100%
3/12/2010	ApaTech Ltd.	Baxter International Inc.	\$330.0	100%
Median of the 18 M&A Transaction Targets			\$144.4	100%

Size of the 18 M&A Transactions (dollars in millions)



Definitions of Financial Terms Used in this Quarterly Industry Update:

Enterprise Value (EV): Market Value of Equity + Market Value of Debt - Cash

Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA): Profitability metric sometimes also referred to as operating profit or operating earnings.

Gross Cash Flows: Net Income + Depreciation and Amortization Expense

Latest Twelve Months (LTM): Financial information is as of the latest twelve months through the date of this Quarterly Industry Update.

Quarterly Industry Update

As of December 31, 2016

Medical Device Industry Aggregates



Comparable Public Company Key Statistics

Median 52-Week Return	7.9%	Median EV/Revenue Multiple	3.8x	Median Price/Earnings Multiple	35.8x
Median Year-to-Date Return	7.9%	Median EV/EBITDA Multiple	16.2x	Median EV/Gross CF Multiple	26.4x

Comparable Public Company Market Price Returns (As of December 31, 2016)

	YTD	3 Month	1 Year	2 Year	3 Year	5 Year	2015	2014	2013	2012	2011
ABIOMED, Inc.	24.8%	-12.4%	24.8%	72.1%	61.5%	43.6%	137.2%	42.3%	99.0%	-27.2%	92.2%
AngioDynamics, Inc.	39.0%	-3.8%	39.0%	-5.8%	-0.6%	2.6%	-36.1%	10.8%	56.1%	-25.8%	-3.6%
Atossa Genetics Inc.	-70.6%	-32.9%	-70.6%	-74.4%	-65.7%	N/A	-77.6%	-38.4%	-40.5%	N/A	N/A
AtriCure, Inc.	-12.8%	23.7%	-12.8%	-1.0%	1.6%	12.0%	12.4%	6.9%	170.7%	-37.8%	8.1%
Becton, Dickinson and Company	7.4%	-7.9%	7.4%	9.1%	14.4%	17.2%	10.7%	25.9%	41.3%	4.6%	-11.6%
BIOLASE, Inc.	66.4%	-20.0%	66.4%	-27.0%	-20.8%	-10.6%	-68.0%	-6.6%	56.1%	-26.6%	52.8%
Boston Scientific Corporation	17.3%	-9.1%	17.3%	27.8%	21.6%	32.3%	39.2%	10.2%	109.8%	7.3%	-29.5%
Cardiovascular Systems, Inc.	60.1%	2.0%	60.1%	-10.3%	-11.0%	19.7%	-49.7%	-12.3%	173.2%	27.4%	-15.5%
CAS Medical Systems, Inc.	-9.0%	-6.9%	-9.0%	-1.2%	-1.8%	-1.6%	7.3%	-2.9%	-20.9%	23.0%	-45.4%
CryoLife, Inc.	77.6%	9.0%	77.6%	30.0%	20.0%	31.9%	-4.9%	2.2%	78.0%	29.8%	-11.4%
Cutera, Inc.	35.7%	45.6%	35.7%	27.5%	19.4%	18.4%	19.8%	4.9%	13.1%	20.8%	-10.1%
Cytosorbents Corporation	-2.2%	-14.8%	-2.2%	-26.0%	20.4%	6.4%	-44.0%	218.4%	-3.8%	-18.8%	14.4%
Daxor Corporation	8.5%	4.7%	8.5%	8.7%	6.5%	-2.0%	8.9%	2.2%	-10.1%	-16.5%	-1.6%
Delcath Systems, Inc.	-88.5%	-62.8%	-88.5%	-78.2%	-75.8%	-74.0%	-58.7%	-70.3%	-79.3%	-59.7%	-68.9%
DexCom, Inc.	-27.1%	-31.9%	-27.1%	4.1%	19.0%	45.0%	48.8%	55.5%	160.6%	46.0%	-31.8%
Endologix, Inc.	-42.2%	-55.3%	-42.2%	-38.8%	-31.0%	-13.0%	-35.3%	-12.3%	22.5%	24.0%	60.6%
EnteroMedics Inc.	-98.5%	-78.8%	-98.5%	-96.3%	-90.2%	-74.3%	-90.8%	-30.4%	-27.1%	64.7%	-44.8%
Escalon Medical Corp.	-90.1%	-84.3%	-90.1%	-74.5%	-62.4%	-36.3%	-34.2%	-18.3%	107.3%	-5.0%	-33.3%
Globus Medical, Inc.	-10.8%	9.9%	-10.8%	2.2%	7.1%	N/A	17.0%	17.8%	92.4%	N/A	N/A
InspireMD, Inc.	-88.6%	21.5%	-88.6%	-88.7%	-84.0%	-74.2%	-88.7%	-68.4%	-36.9%	-55.3%	N/A
LeMaitre Vascular, Inc.	46.9%	27.7%	46.9%	82.0%	46.8%	33.8%	125.5%	-4.5%	39.5%	-3.0%	-12.6%
Merit Medical Systems, Inc.	42.5%	9.1%	42.5%	23.7%	19.0%	14.6%	7.3%	10.1%	13.2%	3.9%	5.7%
MGC Diagnostics Corporation	19.5%	12.7%	19.5%	11.0%	-14.6%	8.6%	3.1%	-49.4%	114.6%	13.0%	0.4%
NeuroMetrix, Inc.	-62.7%	-52.7%	-62.7%	-69.2%	-60.2%	-52.3%	-74.6%	-33.2%	12.5%	-65.4%	-69.4%
NuVasive, Inc.	24.5%	1.1%	24.5%	19.5%	27.7%	39.9%	14.7%	45.9%	109.1%	22.8%	-50.9%
Nxstage Medical, Inc.	19.6%	4.9%	19.6%	20.9%	37.9%	8.1%	22.2%	79.3%	-11.1%	-36.7%	-28.5%
Strata Skin Sciences, Inc.	-60.4%	-17.0%	-60.4%	-39.4%	-59.0%	-58.8%	-7.5%	-81.3%	-64.2%	-51.5%	10.1%
Stryker Corporation	28.9%	2.9%	28.9%	12.7%	16.8%	19.2%	-1.5%	25.5%	37.1%	10.3%	-7.4%
Sunshine Heart, Inc.	-74.1%	-37.5%	-74.1%	-71.3%	-67.0%	N/A	-68.2%	-56.3%	59.4%	N/A	N/A
Tandem Diabetes Care, Inc.	-81.8%	-71.9%	-81.8%	-58.9%	-56.3%	N/A	-7.0%	-50.7%	N/A	N/A	N/A
The Cooper Companies, Inc.	30.4%	-2.4%	30.4%	3.9%	12.2%	19.9%	-17.2%	30.9%	33.9%	31.1%	25.2%
TransEnterix, Inc.	-47.6%	-23.1%	-47.6%	-33.2%	-46.0%	N/A	-14.8%	-64.7%	N/A	N/A	N/A
Utah Medical Products, Inc.	24.3%	21.7%	24.3%	10.1%	8.4%	21.9%	-2.5%	5.1%	58.6%	33.5%	0.4%
Varian Medical Systems, Inc.	11.1%	-9.8%	11.1%	1.9%	4.9%	6.0%	-6.6%	11.4%	10.6%	4.6%	-3.1%
Median of Industry Public Companies	7.9%	-7.4%	7.9%	0.4%	3.3%	8.6%	-5.7%	2.2%	38.3%	4.6%	-8.8%

(Multiple year periods are calculated as the average annual return.)

Quarterly Industry Update

As of December 31, 2016

Medical Device Industry Aggregates



Median Public Company Multiples of the Medical Device Industry Aggregates

Date:	12/31/2014	3/31/2015	6/30/2015	9/30/2015	12/31/2015	3/31/2016	6/30/2016	9/30/2016	12/31/2016
EV/Revenues Multiple	3.0x	3.5x	3.6x	3.1x	3.4x	3.0x	3.1x	3.7x	3.8x
EV/EBITDA Multiple	13.0x	14.5x	14.0x	14.3x	13.3x	14.9x	15.2x	17.2x	16.2x
Price/Earnings Multiple	34.8x	34.9x	36.0x	35.0x	33.4x	34.0x	35.2x	40.7x	35.8x
EV/Gross Cash Flows Multiple	23.0x	27.8x	30.1x	26.8x	40.0x	27.0x	27.2x	28.0x	26.4x

Industry Initial Public Offerings - Medical Device Industry Aggregates (dollars in millions, except share prices)

Offer Date	Company Name	Offer Price	Shares Offered	Amount Raised	Total Assets	Debt	LTM Revenues	LTM EBITDA	LTM Net Income	LTM Cash Flows
12/8/2016	Acaris A/S	\$1.93	8.0	\$15.3	N/A	N/A	N/A	N/A	N/A	N/A
11/3/2016	Neurotech International Limited	\$0.15	35.0	\$5.4	\$2.2	\$0.7	\$0.2	(\$2.7)	(\$3.3)	(\$2.6)
10/5/2016	Obalon Therapeutics, Inc.	\$15.00	5.0	\$75.0	\$20.1	\$9.9	\$3.9	(\$15.4)	(\$16.1)	(\$15.2)
7/12/2016	Vincent Medical Holdings Limited	\$0.13	89.3	\$16.4	\$41.3	\$0.6	\$57.8	\$10.5	\$7.5	\$12.2
5/17/2016	Pulse Biosciences, Inc.	\$4.00	5.0	\$20.0	\$14.3	\$0.0	\$0.0	(\$3.8)	(\$2.8)	(\$3.7)
4/28/2016	PAVmed Inc.	\$5.00	1.1	\$5.3	\$1.2	\$0.0	\$0.0	\$0.0	(\$1.8)	\$0.0
2/28/2016	Invent Medic Sweden AB	\$0.35	3.0	\$1.1	\$0.5	\$0.1	\$0.1	\$0.0	(\$0.1)	\$0.0
11/10/2015	Advanced Accelerator Applications S.A.	\$16.00	4.7	\$75.0	\$233.9	\$27.1	\$88.7	\$1.0	(\$17.3)	\$9.4
6/4/2015	EndoChoice Holdings, Inc.	\$15.00	6.4	\$95.3	\$102.7	\$39.5	\$64.3	(\$39.7)	(\$58.0)	(\$34.1)
1/30/2015	Avinger, Inc.	\$13.00	5.0	\$65.0	\$23.1	\$32.7	\$11.5	(\$23.9)	(\$32.4)	(\$22.4)
12/19/2014	Medovex Corporation	\$5.75	1.4	\$8.0	\$2.6	\$0.0	\$0.0	(\$0.7)	(\$0.7)	(\$0.7)
11/5/2014	Nevro Corp.	\$18.00	7.0	\$126.0	\$62.9	\$0.0	\$26.6	(\$26.5)	(\$26.2)	(\$26.5)
5/7/2014	K2M Group Holdings, Inc.	\$15.00	8.8	\$132.4	\$296.9	\$43.2	\$155.6	(\$8.1)	(\$37.9)	(\$1.6)
4/15/2014	TriVascular Technologies, Inc.	\$12.00	6.5	\$78.0	\$64.7	\$44.3	\$19.5	(\$42.9)	(\$50.3)	(\$41.9)
11/13/2013	Tandem Diabetes Care, Inc.	\$15.00	8.0	\$120.0	\$48.6	\$29.3	\$21.0	(\$37.1)	(\$48.1)	(\$34.2)
10/8/2013	LDR Holding Corporation	\$15.00	5.0	\$75.0	\$78.7	\$53.8	\$98.0	\$2.5	(\$10.3)	\$5.6
8/2/2012	Globus Medical, Inc.	\$12.00	8.3	\$100.0	\$354.8	\$0.0	\$347.9	\$121.4	\$63.9	\$138.8
6/27/2012	Tesaro, Inc.	\$13.50	6.0	\$81.0	\$93.0	\$0.0	\$0.0	(\$23.2)	(\$23.2)	(\$23.2)
4/30/2012	Supernus Pharmaceuticals, Inc.	\$5.00	3.4	\$50.0	\$53.7	\$29.5	\$0.8	(\$36.9)	\$53.8	(\$36.2)
11/17/2011	Sphere Medical Holding PLC	\$1.46	15.1	\$22.1	\$1.5	\$3.8	\$0.0	(\$6.6)	(\$7.0)	(\$6.3)
4/18/2011	InspireMD, Inc.	\$1.50	7.0	\$10.4	\$4.4	\$1.5	\$4.9	(\$3.1)	(\$3.4)	(\$3.0)
2/10/2011	Kips Bay Medical, Inc.	\$8.00	2.1	\$16.5	\$7.2	\$0.0	\$0.1	(\$8.7)	(\$10.2)	(\$8.6)
2/2/2011	Tornier N.V.	\$19.00	8.8	\$166.3	\$499.2	\$133.8	\$223.4	\$13.2	(\$62.1)	\$28.6
11/23/2010	Anacor Pharmaceuticals, Inc.	\$5.00	12.0	\$60.0	\$20.4	\$9.1	\$31.1	(\$4.3)	(\$6.5)	(\$3.6)
Median of All IPOs		nm	nm	\$62.5	\$41.3	\$3.8	\$11.5	(\$4.3)	(\$10.2)	(\$3.6)

Disclosures and Limitations: This research report is for informational and discussion purposes only. Information presented herein is not investment advice of any kind to any person and does not constitute a recommendation as to the purchase or sale of any interests or as to any other course of action. General, financial, and statistical information concerning the details of this report and related industry are from sources Cogent Valuation believes to be reliable. Cogent Valuation has accurately reflected such information in this research report; however, Cogent Valuation makes no representation as to the sources' accuracy or completeness and has accepted this information without further verification. Neither all nor any part of the content of this report may be conveyed to the public through advertising, public relations, news, sales, mail, direct transmittal, or other media without the prior written consent of Cogent Valuation. Cogent Valuation's research is as of the date reported herein. Cogent Valuation has no affiliation with any of the companies comprising the industry used as a basis for research in this report, nor does Cogent Valuation hold any investments in the companies listed herein. The content of this report may be used, in part, as a basis for any work that Cogent Valuation performs for you in the future at the sole discretion of Cogent Valuation. THIS REPORT IS NOT TO BE USED OR CONSIDERED UNDER ANY CIRCUMSTANCE BY ANYONE AS INVESTMENT ADVICE. This industry research is provided at no charge to Cogent Valuation's clients. Research or detailed information not covered in this report can be obtained for a fee. Contact [Steven Kam](mailto:Steven.Kam@CogentValuation.com) at 415-392-0888 for additional information or questions in connection with this research report. Copyright © 2017 Cogent Valuation. All Rights Reserved.